Travoprost

USDailyMed:Travoprost AU:B3 S01EE04(WHO) AU:S4(Prescription only)UK:POM(Prescription only)US:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only) Propan-2-yl 7-[3,5-dihydroxy-2-[3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-but-1-enyl]-cyclopentyl]hept-5-enoate 157283-68-6Y 5282226 7102 DB00287Y 4445407Y WJ68R08KX9 D01964Y CHEBI:746859Y ChEMBL1200799N DTXSID80896948 Interactive image FC(F)(F)c2cc(OC[C@H](O)/C=C/[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(=O)OC(C)C)ccc2 InChI=1S/C26H35F3O6/c1-17(2)35-25(33)11-6-4-3-5-10-21-22(24(32)15-23(21)31)13-12-19(30)16-34-20-9-7-8-18(14-20)26(27,28)29/h3,5,7-9,12-14,17,19,21-24,30-32H,4,6,10-11,15-16H2,1-2H3/b5-3-,13-12+/t19-,21-,22-,23+,24-/m1/s1YKey:MKPLKVHSHYCHOC-AHTXBMBWSA-NY Travoprost, sold under the brand nameTravatanamong others, is amedicationused to treathigh pressure inside the eyeincludingglaucoma.Specifically it is used foropen angle glaucomawhen other agents are not sufficient.It is used as an eye drop.Effects generally occur within two hours. Common side effects include red eyes, blurry vision, eye pain, dry eyes, and change in color of the eyes.Other significant side effects may includecataracts.Use duringpregnancyorbreastfeedingis generally not recommended.It is aprostaglandinanalog and works by increasing the outflow ofaqueous fluidfrom the eyes. Travoprost was approved for medical use in the United States and in the European Union in 2001.It is available as ageneric medicationin the United Kingdom.In 2020, it was the 304th most commonly prescribed medication in the United States, with more than 1million prescriptions.